Ocugen to Host Webcast on Phase 2 Trial Data for Blindness Gene Therapy

Biotech company Ocugen will discuss results for its OCU410 modifier gene therapy for geographic atrophy, a leading cause of blindness.

Mar. 23, 2026 at 11:50am

Got story updates? Submit your updates here. ›

Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced it will host a webcast on Tuesday, March 24, 2026 at 8 a.m. EDT to discuss data from the Phase 2 ArMaDa clinical trial evaluating its OCU410 gene therapy for geographic atrophy, a late-stage form of dry age-related macular degeneration. Key opinion leaders and Ocugen executives will participate in the webcast to present the full data set and answer questions.

Why it matters

Geographic atrophy is a leading cause of blindness that affects millions of people globally, and there are currently no approved treatments. Ocugen's modifier gene therapy approach aims to address the underlying imbalances in multiple gene networks that contribute to the disease, potentially offering a new therapeutic option for patients.

The details

The webcast will feature presentations from several key opinion leaders in ophthalmology, including Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology at Duke University; Jay Chhablani, MD, Professor at the University of Pittsburgh; Victor H. Gonzalez, MD, Retinal Surgeon at Valley Retina Institute; and Syed M. Shah, MD, Vice Chair for Research and Digital Medicine at Emplfiy Health. They will discuss the full data set from the Phase 2 ArMaDa trial evaluating Ocugen's OCU410 gene therapy for geographic atrophy.

  • The webcast will be held on Tuesday, March 24, 2026 at 8 a.m. EDT.

The players

Ocugen, Inc.

A pioneering biotechnology company focused on gene therapies for blindness diseases.

Lejla Vajzovic, MD, FASRS

Professor of Ophthalmology and Director of CME-Ophthalmology at Duke University School of Medicine, and Chairman of Ocugen's Scientific Advisory Board.

Jay Chhablani, MD

Professor at the University of Pittsburgh and UPMC Vision Institute, and President of NetraMind.

Victor H. Gonzalez, MD

Retinal Surgeon at Valley Retina Institute, McAllen, Texas, and Faculty at the University of Texas Rio Grande Valley.

Syed M. Shah, MD

Vice Chair for Research and Digital Medicine, Director of Retina Service, Department of Ophthalmology at Emplfiy Health, La Crosse, WI, and Ibn al-Haytham Professor, Department of Ophthalmology, Aga Khan University.

Got photos? Submit your photos here. ›

What they’re saying

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Ocugen's modifier gene therapy approach for geographic atrophy, a leading cause of blindness, represents a potentially groundbreaking advancement in the treatment of complex eye diseases that affect millions globally. The upcoming webcast will provide important insights into the Phase 2 trial data and the company's progress in developing this innovative therapy.